Welcome to the Medical Valley network, VR NeuroLink AI!
We are excited to welcome VR NeuroLink AI as the newest member of the Medical Valley network. The company develops a clinical virtual reality platform designed to modernize neurodiagnostics and rehabilitation for patients with balance and central nervous system disorders.
In an exclusive interview, CEO Raman Tsimafeyev talks about the company’s vision, the innovative approach of combining diagnostics and therapy in a single workflow, the role of clinical partnerships in developing the platform, and their plans to expand visibility and impact in Germany and beyond.
Can you briefly introduce VR NeuroLink AI and explain its role in modernizing neurodiagnostics and rehabilitation?
VR NeuroLink AI is a medical VR platform being developed as a Class IIa medical device, designed for objective neurodiagnostics and measurable neurorehabilitation in patients with balance and central nervous system disorders.
The platform already translates stabilometric assessment principles — the clinical gold standard for balance evaluation — into a clinically usable VR environment. This approach has been tested and validated in real clinical settings and enables diagnostics and rehabilitation to be combined into a single, continuous clinical workflow.
VR NeuroLink AI reduces reliance on subjective assessment and provides clinicians with quantitative, reproducible data applicable both at the diagnostic stage and throughout rehabilitation monitoring.
What makes your platform unique, and how does it improve measurable outcomes for patients?
The uniqueness of VR NeuroLink AI lies in its diagnostic-first approach. Unlike most VR rehabilitation solutions that focus primarily on therapeutic exercises, our platform is built around objective measurement of neurofunctional parameters.
It enables quantitative assessment, longitudinal tracking, and data-driven adjustment of rehabilitation protocols. This creates a measurable link between diagnosis, therapy, and clinical outcomes, improving reproducibility and clinical decision-making.
How has working with clinics shaped your platform, and what role do partnerships play in your development?
VR NeuroLink AI has been shaped through close collaboration with clinical partners from early development stages. Clinical practice demonstrated that the main limitation is not the absence of diagnostic standards, but their limited usability in everyday clinical workflows.
Clinical partners played a key role in adapting stabilometric methodologies for early rehabilitation phases, patients with reduced mobility, and real-world clinical constraints. For us, partnerships represent a source of clinical expertise, validation, and trust rather than simply a deployment channel.
How do you plan to increase VR NeuroLink AI’s visibility in Germany and beyond?
Germany is the primary entry market for VR NeuroLink AI. The project already collaborates with German clinical partners and is part of the Medical Valley ecosystem, as well as relevant medical and industrial clusters.
Visibility growth is driven through clinical pilots, academic collaborations, participation in professional medical communities, and step-by-step integration into existing clinical and regulatory pathways rather than mass-market promotion.
What do you hope to achieve through your Medical Valley membership?
Medical Valley represents an ecosystem where clinical practice, science, industry, and regulatory processes intersect.
We seek expert support in regulatory strategy, clinical validation, and integration into the German healthcare system. We are open to collaboration with universities, clinics, and industry partners and view Medical Valley as a key platform for long-term presence and scaling in Germany.